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Background: Novel therapies need to be evaluated in normal clinical practice to allow a true representation of the
treatment effectiveness in real-world settings.
Methods/design: The Salford Lung Study is a pragmatic randomised controlled trial in adult asthma, evaluating
the clinical effectiveness and safety of once-daily fluticasone furoate (100 μg or 200 μg)/vilanterol 25 μg in a novel
dry-powder inhaler, versus existing asthma maintenance therapy. The study was initiated before this investigational
treatment was licensed and conducted in real-world clinical practice to consider adherence, co-morbidities,
polypharmacy, and real-world factors. Primary endpoint: Asthma Control Test at week 24; safety endpoints
include the incidence of serious pneumonias. The study utilises the Salford electronic medical record, which
allows near to real-time collection and monitoring of safety data.
Discussion: The Salford Lung Study is the world’s first pragmatic randomised controlled trial of a pre-licensed
medication in asthma. Use of patients’ linked electronic health records to collect clinical endpoints offers
minimal disruption to patients and investigators, and also ensures patient safety. This highly innovative study
will complement standard double-blind randomised controlled trials in order to improve our understanding
of the risk/benefit profile of fluticasone furoate/vilanterol in patients with asthma in real-world settings.
Trial registration: Clinicaltrials.gov, NCT01706198; 04 October 2012.
Keywords: Asthma, Electronic medical record, Fluticasone furoate/vilanterol, Inhaled corticosteroid/long-acting
β2-agonist, Pragmatic randomised controlled trial, Real-world evidenceBackground
Combination of a long-acting inhaled corticosteroid
(ICS) fluticasone furoate (FF) with the novel long-acting
β2-agonist (LABA) vilanterol (VI) in a novel dry-powder
inhaler (DPI; Ellipta®) has been investigated as a once-
daily medication for the management of asthma [1]. Fol-
lowing a phase III programme of randomised controlled
trials (RCTs), marketing authorisation was given by the
European Commission on 18 November 2013 and FF/VI* Correspondence: ashley.woodcock@manchester.ac.uk
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We have previously described the principles behind the
Salford Lung Study (SLS) and how this pragmatic RCT
(pRCT) differs from standard RCTs [2]. The study was ori-
ginally designed and approved before the investigational
treatment received regulatory approval, and hence is a
phase III study. It compares the FF/VI combination with
existing maintenance therapy, in a large population of
patients with asthma, studied in real-world routine clinical
practice, and monitored using an electronic medical
record (EMR). Here we provide details of the SLS asthma
protocol.ticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Study design
SLS is a 12-month randomised, open-label, phase III
pRCT evaluating the effectiveness and safety of FF/VI
(Relvar®; 100 μg/25 μg or 200 μg/25 μg once daily, deliv-
ered by a novel DPI [Ellipta®] in patients with asthma)
(clinicaltrials.gov identifier NCT01706198) (Fig. 1). The
study is conducted in accordance with the International
Conference on Harmonisation, Good Clinical Practice
(GCP), all applicable data protection requirements
and the ethical principles outlined in the Declaration
of Helsinki 2013 (National Research Ethics Service
Committee North West, Greater Manchester South;
Research Ethics Committee reference 12/NW/0455).
The study protocol conforms to the SPIRIT 2013
statement (Standard Protocol Items: Recommenda-
tions for Interventional Trials [3, 4]).
The Salford Lung Study team sought guidance on the
study design under the joint scientific advice process from
National Institute for Health and Care Excellence and the
Medicines and Healthcare Products Regulatory Agency; a
joint consultation process took place to seek guidance on
the study design. Informal discussions and advice on the
study design took place prior to formal ethics application
from the National Research Ethics Service Committee
North West, Greater Manchester South.
Patients
All patients with asthma at 66 primary care sites (at the
time of manuscript preparation) in and around SalfordFig. 1 Study design. *Cardiovascular risk factors collected. †Comprises: Asth
questionnaire; Medication Adherence Report Scale for Asthma; Work P
FF fluticasone furoate; GP general practitioner; ICS inhaled corticosteroand South Manchester are identified from practice data-
bases, and invited to participate in the study by their own
general practitioner (GP) (Fig. 1).
Eligibility criteria include:
 aged ≥18 years
 symptomatic asthma diagnosed by a GP
 regular maintenance inhaler therapy with ICS or
ICS/LABA
 symptoms within the week prior to visit 2.
There are minimal exclusion criteria such as a recent his-
tory of life-threatening asthma, chronic obstructive
pulmonary disease or other clinically significant disease
that would jeopardise patient safety. Eligible patients are
recruited for the study in GPs’ offices. At visit 1, patients
are offered study participation through written consent.
At visit 2 (0–30 days after visit 1), patients are randomised
1:1 to receive FF/VI or continue on usual asthma mainten-
ance therapy (ICS or ICS/LABA). The randomisation at
visit 2 is stratified by Asthma Control Test (ACT) score
(≥20, 16 to 19, or ≤15) and by previous asthma mainten-
ance therapy (ICS or ICS/LABA). Patients randomised to
continue their existing asthma maintenance therapy arm
do not receive FF/VI. During the study, the doses of all
medication may be adjusted at the GP’s discretion in the
usual way. Both study groups receive free prescriptions for
study medication, which is collected by the patients from
local community pharmacies, and prescription data are
captured on the electronic case report forms (eCRFs).ma Control Test; Asthma Quality of Life Questionnaire(s); EuroQol
roductivity and Activity Impairment Questionnaire: Asthma.
id; LABA long-acting β2-agonist; VI vilanterol
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Primary care
To preserve the real-world nature of the study, the patient
experience is as close to routine care as possible. The
study’s principal investigators are the patients’ own GPs
who may make treatment adjustments according to their
clinical opinion. GPs make repeat prescriptions of study
medication as usual, which are collected by patients from
their usual pharmacy. GPs are ideally placed to facilitate
recruitment, identify and report serious adverse events
(SAEs) or serious adverse drug reactions (ADRs), and
report study endpoints. As very few participating GPs had
experience of clinical trial participation, all GPs have
received training and support in GCP, patient recruitment,
the study protocol, coding of healthcare issues and general
research procedures.
Pharmacy
Every pharmacy in Salford and others in South Manchester
have agreed to participate in the study, even though very
few of the pharmacists had experience of clinical trial par-
ticipation. Standard operating procedures were established,
and more than 500 staff at participating pharmacies have
received training in GCP and safety reporting. Initially
pharmacies faxed copies of all prescriptions for collected
study treatments to the study coordination centre, but as
the trial progressed this has been collected electronically.
Hospitals
The large majority of admissions are to the local Salford
Royal Hospital and the University Hospital of South
Manchester where admissions are tracked electronically
and in near-real time. Occasionally patients are admitted
to other hospitals. These admissions are tracked via the
primary care records. Information relating to all hospita-
lisations is reviewed by a dedicated study safety team.
Data monitoring
All hospital admissions, outpatient and emergency
department visits are identified from the EMR database
(whenever and wherever they occur). From primary care,
all healthcare contacts, out-of-hours activity and pre-
scriptions of antibiotics or oral steroids can be identified.
These events are reviewed by the study research team
and classified as asthma or non-asthma related. Further-
more, the EMR captures suspected unexpected serious
adverse reactions (e.g. reduced kidney function or
elevated liver function tests) and, for the purposes of
SLS, includes data from external sources to identify, for
example, deaths or National Health Service (NHS) hos-
pital admissions outside Salford. Northwest EHealth [5]
manages the EMRs, enabling data on study endpoints
and patient safety to be collected continuously and
remotely in near-real time.Endpoints
Efficacy
The primary endpoint is the percentage of patients in
each treatment arm, who have either an ACT total score
of ≥20 or an increase from baseline of ≥3 in ACT total
score at week 24 assessment. Secondary efficacy end-
points include: the percentage of patients who have
either an ACT total score of ≥20 or an increase from
baseline of ≥3 in ACT total score at weeks 12, 40 and
52; the mean change from baseline in ACT total score at
weeks 12, 24, 40 and 52; and the percentage of patients
with an ACT total score ≥20 at weeks 12, 24, 40 and 52.
Further details of trial endpoints can be found in Table 1.
Randomisation is stratified by baseline asthma therapy
(ICS or ICS/LABA) and ACT score (≤15, 16–19, ≥20) to
ensure treatment groups are balanced on disease severity
and level of asthma control. These randomisation strati-
fication variables will be included in the primary analysis
model as covariates. Subgroup summaries and/or ana-
lysis will also be provided by the randomisation stratifi-
cation variables, when appropriate.
Safety
Safety endpoints include the frequency and type of SAEs
and ADRs, and the incidence of SAEs of pneumonia
during the study. SAEs are monitored continually
through the patient’s EMR. GPs/investigators or site staff
are responsible for detecting, documenting and report-
ing SAEs and non-serious ADRs, identified by hospital-
isation alerts through EMR and reported on eCRFs, with
additional monitoring by telephone every 3 months.
Statistical analysis
A sample size of 2906 patients (1453 patients per treatment
group) will detect a treatment difference of 6 % between
usual asthma maintenance therapies and FF/VI on the
primary endpoint, at the significance level 0.05 and 90 %
power (assuming 50 % response rate in the usual asthma
maintenance group at 6 months). A total of 4036 patients
are required in the intent-to-treat (ITT) population
(randomisation of 2018 patients per treatment arm) in
order to have at least 2906 patients in the primary efficacy
analysis population, assuming 80 % of patients in the ITT
population have an ACT score of <20 at baseline and a
10 % dropout rate over the first 6-month period.
Primary efficacy analysis population is all ITT patients,
who have an ACT total score <20 at baseline (randomisa-
tion visit). Treatment difference between the two treatment
arms will be analysed using logistic regression adjusting for
baseline ACT total score, baseline asthma therapy per
randomisation stratification (ICS or ICS/LABA), age and
gender. Subgroup analyses, when appropriate, will be pro-
vided for efficacy and safety endpoints based on baseline
disease characteristics per randomisation stratification.
Table 1 Study endpoints
Endpoint Definitions
Primary endpoint The primary efficacy analysis population is defined as all ITT patients
who have an ACT total score of <20 at baseline
The percentage of patients who have either an ACT total score of ≥20
or an increase from baseline of ≥3 at week 24 (6th month) assessment
Secondary efficacy endpoints • All contacts are any encounter the patient may have with a
doctor or nurse or other healthcare professionals working as
part of the NHS (including telephone calls). Contacts with the
NHS or hospitalisation are defined as exacerbation-related
contacts if these contacts were a direct result of an acute
worsening of asthma symptoms. Contacts are defined to be
asthma-related as per GP/investigator-defined normal clinical
practice. These contacts do not include protocol-defined
study-related visits/contacts
• A prescription of systemic corticosteroid or antibiotics is defined
as exacerbation-related if the reason the drug was given, in whole
or in part, was to treat an acute worsening of asthma symptoms
• A severe asthma exacerbation is defined as deterioration of asthma
requiring the use of systemic corticosteroids (tablets, suspension or
injection) or antibiotics, an inpatient hospitalisation, or emergency
department visit due to asthma that required systemic corticosteroids
or antibiotics. Exacerbation-related hospitalisation includes
hospitalisation that is prolonged as a result of an asthma exacerbation
• Percentage of patients who have either an ACT total score of ≥20 or
an increase from baseline of ≥3 in ACT total score at weeks 12, 40 and 52
• Percentage of patients with ACT total score ≥20 at weeks 12, 24, 40 and 52
• Mean change from baseline in ACT total score at weeks 12, 24, 40 and 52
• All/asthma-related primary or secondary care contacts
• Mean annual rate of severe asthma exacerbations
• Number of salbutamol inhalers (adjusted to equivalence of 200 actuations)
dispensed from study-enrolled community pharmacies over the entire
treatment period
• Time to discontinuation or modification of initial therapy (i.e. therapy
the patient is randomised to at visit 2)
• Percentage of patients who have an increase from baseline of ≥0.5
in AQLQ(s) total score at week 52
• Percentage of patients who have an increase from baseline of ≥0.5 in
AQLQ(s) environmental stimuli domain score at week 52
Safety endpoints • An ADR is any untoward medical occurrence in a patient
temporally associated with the use of a medicinal product, for
which there is a reasonable possibility that the untoward
occurrence is causally related to the medicinal product
• An SAE is any untoward medical occurrence that, at any dose:
results in death; is life-threatening; requires hospitalisation or
prolongation of existing hospitalisation; results in disability/
incapacity; is a congenital anomaly/birth defect; subject to medical
or scientific judgement, may jeopardise the patient or may require
medical or surgical intervention to prevent one of the other
outcomes listed
• Incidence of SAEs of pneumonia during the study
• Time to first SAE of pneumonia
• Deaths due to serious events of pneumonia
• Frequency and type of SAEs
• Frequency and type of ADRs
Other efficacy endpoints • Increase from baseline of ≥0.5 in AQLQ(s) refers to: total score
at week 24; individual domain scores at week 24; individual
domain scores (symptoms, activity, limitations and emotional
function) at week 52
• WPAI: asthma at week 52 refers to the following categories:
percentage of work time missed due to asthma: percentage of
impairment while working due to asthma; percentage of overall
work impairment due to asthma; percentage of activity impairment
due to asthma
• Mean change from baseline in individual question scores for ACT at
weeks 12, 24, 40 and 52
• Mean change from baseline in total score and domain scores of AQLQ(s)
at weeks 24 and 52
• Percentage of patients who have an increase from baseline of ≥0.5 in AQLQ(s)
• WPAI: asthma at week 52
• Health status using the EQ-5D at week 52
• Adherence with study medication based on analysis of medications
(prescribed, dispensed and collected) during the study
• Use of the MARS-A at week 52
ACT Asthma Control Test, ADR adverse drug reaction, AQLQ Asthma Quality of Life Questionnaire, EQ-5D EuroQol questionnaire, GP general practitioner, ITT
intent-to-treat, MARS-A Medication Adherence Report Scale for Asthma, NHS National Health Service, SAE serious adverse event, WPAI Work Productivity and
Activity Impairment Questionnaire
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Guidelines on treatment options are primarily based on
double-blind RCTs (DBRCTs) [6, 7]. However, RCTs for
registration purposes do not represent real life. Multiple
inclusion and exclusion criteria mean that only a small
proportion of patients with asthma (~5 %) are repre-
sented in DBRCTs, and patients with co-morbidities are
excluded. In addition, only restricted outcomes are
assessed (e.g. forced expiratory volume in 1 second), and
studies are of short duration (<6 months). Finally,
patients are closely monitored and inhaler technique re-
peatedly checked, so that adherence levels exceed 90 %,
compared with less than 40 % in observational studies.Although observational studies provide opportunities
to assess real-world outcomes, the lack of suitable
comparison between treatment groups and the small
patient numbers in prospective trials can be limiting [8].
Consequently, the true impact and value of treatments
for asthma may not be fully reflected by observational
studies and DBRCTs.
The SLS is the first phase III pRCT study in asthma initi-
ated while the investigational treatment was an un-licensed
medicine, where supervision and monitoring of patients
are reduced to a minimum. Clinical endpoints are collected
and patient safety is guaranteed with remote clinical sur-
veillance in near to real-time through the EMR. The study
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care providers to assess effectiveness, adherence levels and
the true value of FF/VI treatment in the real world.
The primary endpoint, ACT, was chosen to reflect im-
pact of treatments on patients’ overall asthma control.
The rate of severe asthma exacerbations as a primary end-
point would not have been feasible due to the infrequent
occurrence of such events in a general asthma population
[9]; consequently, the number of eligible patients with
asthma in the study population is insufficient to have
adequate statistical power for an exacerbation study. How-
ever, although ACT may reflect a dimension of asthma
that is different from exacerbations, it is not merely a
proxy for exacerbations.
This pRCT has been a major challenge in study design,
operational planning and study support. It has been
possible because the SLS is focused on a single geograph-
ical area in the UK, with a stable population with high
respiratory morbidity, and where healthcare is managed
by the NHS. Salford and the surrounding area are unique
in having a longstanding EMR connecting primary and
secondary care together with local pharmacies. The extent
to which these data will be transferable will depend on
local health service provision, but SLS should provide a
model for future assessments of the clinical effectiveness
of new treatments.
In summary, data from the SLS will complement
results from conventional registration trials, allowing a
better understanding of the risk/benefit profile of the
FF/VI combination in the wider community of patients
with asthma.
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